Based on the cBioPortal database, we found that TP53 mutation was present in more than 60% of ATC patients much more than in other thyroid cancer patients (PTC, FTC, and PDTC), and significantly associated with the overall survival of patients with thyroid cancer (p = 0) (Supplementary Figure 4). Here, TP53 is linked to thyroid cancer, nonmedullary, 2.